🎉 M&A multiples are live!
Check it out!

Public Comps and Valuation Multiples
for FemTech

Benchmark revenue and EBITDA valuation multiples for public comps like Jiangsu Bioperfectus, Curves Holdings Co., Neurocrine Biosciences, Abbott India and InMode.

Company	EV	EV/LTM Revenue	EV/LTM EBITDA
Hologic	$17.1B	4.1x	12.6x
Neurocrine Biosciences	$13.4B	4.7x	20.3x
Organon	$10.0B	1.6x	5.2x
Abbott India	$6.5B	8.6x	31.4x
Olema Pharmaceuticals	$1.7B	n/a	-9.9x
Jiangsu Bioperfectus	$661M	n/a	n/a
Curves Holdings Co.	$451M	1.8x	7.9x
InMode	$411M	1.1x	4.3x
Applied BioCode	$54.1M	n/a	n/a
Elutia	$49.3M	2.6x	-5.5x
Context Therapeutics	$42.6M	n/a	n/a
Atossa Therapeutics	$28.4M	n/a	n/a
Veru	$19.6M	n/a	n/a
Movano	$8.1M	n/a	n/a
Dare Bioscience	$7.9M	10.4x	n/a
Futura Medical	$3.7M	n/a	n/a